Fertility innovation is poised to take centre stage at Femtech World’s third annual awards event, with entries closing in just one week.

The Femtech World Awards recognise outstanding leadership, innovation and impact across key areas of women’s health and wellbeing.

Among the categories is the Fertility Innovation of the Year award, which honours a pioneering product, service or initiative driving transformation in fertility care and support.

Shortlisted entries will demonstrate exceptional innovation in helping individuals or couples along their fertility journeys,  whether through technology, treatments, education, accessibility or emotional support.

Judges will assess scientific advancement, inclusivity, user impact and the potential to break down barriers in fertility health.

The award is sponsored by FinDBest IVF, a global B2B digital platform designed to simplify and accelerate connections between IVF and ART manufacturers and trusted, pre-vetted distributors worldwide.

Since its launch in 2024, the platform has tackled a longstanding challenge in the MedTech sector – fragmented, costly and inefficient market access – by providing a curated, country-specific directory of active partners, featuring key segmentation, certification indicators and direct contact tools.

Covering everything from consumables and lab equipment to AI-powered embryo selection and genetic testing solutions, FinDBest enables companies to scale internationally without the need for expensive congresses or cold outreach.

Juan A. Jiménez, founder and CEO of FinDBest IVF, said: “As part of its commitment to driving smarter access to reproductive innovation, FinDBest IVF is proudly supporting the Femtech World Fertility Innovation Awards for the second year in a row.

“This collaboration reflects two core beliefs at the heart of the platform.

“First, FinDBest IVF was created to accelerate not only the discovery of innovative fertility solutions but their global adoption.

“By supporting these awards, the platform helps amplify breakthrough technologies—from AI-based egg quality tools to next-gen IVF microdevices—and ensures they can reach the right partners and clinics faster.

“Second, the Awards align with FinDBest’s vision of building a 360-degree commercialisation ecosystem, where innovation is not just recognised, but connected to real-world opportunities.

“Many award nominees are pioneering startups and clinical researchers—exactly the kind of innovators who benefit from FinDBest’s support in navigating regulatory complexity, distributor validation, and go-to-market strategies across diverse regions.

“Together with Femtech World, FinDBest IVF is helping to spotlight, support, and scale the future of fertility care.”

Find out more about the Femtech World Awards and enter for free here.

Mifepristone, widely used in medical abortions, may also lower breast cancer risk in women more likely to develop the disease.

Doctors and scientists say stigma surrounding mifepristone is deterring pharmaceutical firms from examining its use as a preventive drug, even though three studies suggest it can slow cancer cell growth.

They argue the drug’s link with abortion, along with restrictions in some countries, is blocking research that could have major public health benefits.

Mifepristone is one of two drugs, along with misoprostol, that women in the UK can use to end pregnancies up to 10 weeks.

Women take a mifepristone tablet, wait 24–48 hours and then take misoprostol. It works as a selective progesterone receptor modulator, meaning it blocks progesterone – a hormone known to drive cell growth in breast cancer.

“It is deeply disappointing that the successful application of mifepristone in one area of clinical medicine is hindering more extensive research into other indications that could benefit public health,” the eight co-authors wrote in The Lancet Obstetrics, Gynaecology and Women’s Health.

“The time is long overdue to give mifepristone the opportunity it deserves to be investigated as a non-surgical option for primary prevention.”

The authors, specialists in reproductive health and cancer, are based in London, Edinburgh, Stockholm and Erbil, Iraq.

Breast cancer kills about 670,000 women worldwide each year, according to the World Health Organization.

Mifepristone could prove particularly useful for women with BRCA1 or BRCA2 gene variants, who currently face limited choices beyond mastectomy or what the authors describe as “low efficacy” drugs.

Three small studies carried out in 2008, 2022 and 2024 showed the drug reduced progesterone’s effect on breast tissue cell growth.

UK cancer charities have joined calls for further research.

Dr Simon Vincent, chief scientific officer at Breast Cancer Now, said: “More risk-reducing treatment options for women with a high risk of developing breast cancer, that also protects their quality of life, are desperately needed. And we need to explore all avenues, including existing drugs, to achieve this.

“So early research into mifepristone is an important step forward and we need further studies to understand if these drugs are safe and effective.”

Dr Marianne Baker, Cancer Research UK’s science engagement manager, pointed to the UK’s 57,900 annual breast cancer cases as evidence that “it’s vital we invest in research exploring new ways to prevent the disease”.

She added: “Cancer develops when cells grow uncontrollably. Early studies showed that mifepristone slowed down cell growth in breast tissue, so it might be useful in delaying or preventing cancer.

“But we need more research to understand whether it’s effective, how it works and who would benefit most from it.”

Prof Kristina Gemzell Danielsson, the lead author and head of the department of women’s and children’s health at the Karolinska Institute in Stockholm, said: “Stigma around mifepristone used for abortion is describing part of why mifepristone is not more extensively researched for prevention of breast cancer.

“Taken together, our data support the use of mifepristone for prevention of poor prognosis breast cancer. All studies were randomised controlled trials using a low dose of mifepristone for two or three months.”

Missed medical appointments cost billions, and can mean the difference between early detection and a devastating diagnosis. A pioneering AI platform is tackling medical ‘no-shows’ and getting more women into lifesaving cervical screenings.

The US loses US$150bn to missed medical appointments each year, with the cost of no-shows thought to be around £1.2bn in the UK.

Not only do these missed appointments have a huge financial burden, but they oftendelay diagnosis and treatment that could potentially save lives.

“One of the biggest problems in healthcare, especially in the US, is no-shows,” says Neil Dunwoody, co-founder and COO of medtech company, SPRYT.

“On top of that, over $1 trillion – more than a quarter of the entire US healthcare budget – is spent on administration and scheduling alone. And this isn’t just a US issue. No-shows and the costs of getting patients to their appointments are global challenges. There isn’t a single health system in the world that’s unaffected.”

In a bid to reduce the number of missed medical appointments, including oncology screenings, SPRYT has developed an agentic AI platform, designed to simplify the process of booking appointments.

ASA’s predictive model is capable of forecasting appointment no-shows with up to 92 per cent accuracy, reducing communication costs by 30 per cent.

From sport to healthcare

Initially a sports platform, linking people with others who wanted to take part in activities, SPRYT looked at algorithms that could predict whether someone would show up for activities such as a five-a-side match or a tennis game.

“We realised that, if that kind of behavioral data exists, why not apply it to healthcare? After all, there’s even more data available, and in many ways, the motivations are more explainable,” says Dunwoody.

“People might skip five-a-side because they’re anxious about who they’re playing against. But in healthcare, someone might miss an oncology appointment because they’re terrified of what they might hear. The emotional barriers are very real, and very different.”

For Dunwoody and co-founder Daragh Donohoe, the project became personal when they lost a close friend to cancer.

“He had back pain and was referred for an MRI, but couldn’t make the appointment,” says Dunwoody.

“He tried to reschedule, but the system made it so difficult that he just gave up. A year later, he was diagnosed with stage four cancer and passed away shortly after.”

Since the Covid-19 pandemic, these problems have been exacerbated, and with many GPs only offering a short time slot in the mornings to book appointments, being seen by a healthcare professional can be difficult.

“The truth is that health systems are built for administrators, not for patients. We decided to flip that,” Dunwoody adds.

Meeting patients where they are

In order to reach patients more easily, the platform uses common messaging platforms such as Whatsapp.

“We realised early on that there was no point building another app. There are already too many healthcare apps with low engagement. People just don’t use them,” Dunwoody explains.

“Instead, we looked at how people communicate. Your SMS inbox is filled with banks, utilities, spam, and scams. But your WhatsApp or Messenger threads? That’s where your friends, family, and loved ones are. People you trust. So why not manage your healthcare there?

“It’s free for patients, far cheaper for health systems than SMS, phone calls, or letters, and critically, it’s where people are most responsive. That’s why we built the system the way we did – not around apps, but around the channels people already live in.

“We were the first company in the world to integrate WhatsApp and generative AI into a live health system, specifically with the NHS’ EMIS system.”

How ASA works

At the core of the platform are two key models – a no-show prediction model, predicting with up to 92 per cent accuracy whether someone is likely to miss their appointment, and a no-show reduction model which helps to change no-show outcomes using behavioural science, linguistics, and psychology.

The no-show prediction model combines historical data pulled from electronic medical records, synthetic data to simulate millions of potential reasons someone might not show up, and live conversational data.

“The live conversational data is where it gets really powerful,” says Dunwoody.

“ASA is a fully conversational agent that can speak in 161 different languages. Through these conversations, we can detect all sorts of signals: fear, hesitation, low health literacy, whether English is someone’s first language, and so on.

“ASA analyses how people respond, whether they hesitate, how fast they reply, if they seem confused, and adapts in real time. If someone isn’t understanding the message, ASA can rephrase it, simplify it, or switch to another language to make sure they get it.

He continues: “With the no-show reduction model, the goal is to get the patient to do one of three things: book the appointment, reschedule it, or cancel ahead of time, so that slot can be filled by someone else.

“Most systems stop at prediction. They flag the risk and leave it to the health service to act. What makes ASA different is that it engages directly with the patient, in a natural, empathetic conversation.”

SPRYT has also developed a Retrieval-Augmented Generation (RAG) model which ensures the AI is always referencing pre-approved, accurate information such as FAQs from clinic websites, official guidelines from organisations, and operational information like clinic locations, parking, or childcare availability.

Additionally, Dunwood explains, in areas where literacy or language barriers are common or where people are visually impaired, SPRYT has developed a feature called “voice note tennis.”

ASA sends a voice message in the patient’s preferred language, and they reply the same way.

“It’s more natural, more human, and genuinely accessible,” he adds.

Boosting cervical screenings in the NHS

Following a successful pilot focused on improving take-up of the HPV vaccine, ASA is currently operating within the NHS in north central London, managing cervical cancer screening appointments, and has already seen promising results.

“Booking rates for cervical screenings jumped from 10 per cent to 160 per cent,” says Dunwoody.

“Administrative workloads dropped by over eight hours per week per clinical administrator. We’ve achieved a 33 per cent reduction in SMS costs and over 60 per cent when you factor in saved costs from letters and phone calls. Now, 25 per cent of patients book outside normal office hours, often at night or early morning. That’s the beauty of ASA, it doesn’t sleep.”

Alongside this, SPRYT is also working on other initiatives to support the NHS’s objective of eliminating cervical cancer by 2040, such as providing women with at-home screening tests.

“We contact a patient twice for smear tests and, if they don’t respond or book, we’ll send them an at-home cancer screening test,” says Dunwoody.

“There is a big push in the redirection of NHS England, to keep patients out of hospitals or clinics, and the best way to do that is at home testing for things like this.”

Meanwhile, in the US, the SPRYT ASA platform is now part of the Mayo Clinic innovation exchange, and the company is looking at rolling out a programme at Cleveland Clinic, as well as looking to expand into other areas of healthcare including diabetes and lung screening.

SPRYT’s ASA platform won Femtech World’s Cancer Innovation of the Year Award 2025.